Navigator Medicines at the 2025 EADV Conference
A First-in-Human Phase 1a Randomized, Double-Blind, SingleAscending Dose Study of NAV-240, an anti-OX40L/TNF-α Bispecific Antibody, in Healthy Volunteers
A First-in-Human Phase 1a Randomized, Double-Blind, SingleAscending Dose Study of NAV-240, an anti-OX40L/TNF-α Bispecific Antibody, in Healthy Volunteers